IDWeek 2014: HIV

Insulin-like growth factor (IGF-1) and sex steroid hormones were not associated with changes in bone mineral density (BMD) in HIV- and HCV-infected patients, but IGF-1 levels were significantly decreased in HCV and negatively correlated with liver disease severity.

Use of prescription erectile dysfunction (ED) medication was significantly associated with sexual risk behavior in HIV-positive men.

Dually treated HIV/HBV co-infected patients had a higher risk of hip fracture than HBV mono-infected, antiretroviral therapy (ART)-treated HIV-mono-infected, and HIV/HBV uninfected patients.

Earlier initiation of antiretroviral therapy (ART) significantly lowered mortality in patients with HIV and tuberculosis (TB) co-infection, despite a higher incidence of immune reconstitution inflammatory syndrome (IRIS).

Women who are HIV positive and pregnant have high rates of preterm delivery (PTD) and deliver children who are small for gestational age (SGA) in Canada.

Hyperbilirubinemia does not appear to influence persistence with atazanavir (ATV) in a “real-world setting”.

Switching to single-tablet co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir (EVG/COB/FTC/TDF) from a multi-tablet ritonavir-boosted protease inhibitor (PI + RTV) with emtricitabine and tenofovir DF (FTC/TDF) regimen significantly increased rates of virologic suppression and declined fasting triglycerides in patients with HIV-1 infection.

Results from a cohort analysis showed no evidence of an increased risk of suicidality or suicide attempt among patients starting an efavirenz-containing compared to an efavirenz-free regimen.

The use of isoniazid as preventive therapy among HIV-infected patients receiving highly active antiretroviral therapy (HAART) is associated with significantly lower tuberculosis incidence.

Treatment with rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) was noninferior to efavirenz (EFV/FTC/TDF) in treatment-naïve patients with HIV at Week 48.